Egetis Therapeutics (Sweden) Today
| EGTX Stock | SEK 6.47 0.49 7.04% |
Performance5 of 100
| Odds Of DistressOver 63
|
Egetis Therapeutics is selling for under 6.47 as of the 4th of May 2024; that is -7.04 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 6.2. Egetis Therapeutics has more than 63 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Egetis Therapeutics AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of April 2024 and ending today, the 4th of May 2024. Click here to learn more.
Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. The company has 249.59 M outstanding shares. More on Egetis Therapeutics AB
Moving against Egetis Stock
| 0.58 | HNSA | Hansa Biopharma AB | PairCorr |
| 0.52 | GENO | Genovis AB | PairCorr |
Egetis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Egetis Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Egetis Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Egetis Therapeutics AB (EGTX) is traded on Stockholm Exchange in Sweden and employs 17 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.51 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Egetis Therapeutics's market, we take the total number of its shares issued and multiply it by Egetis Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Egetis Therapeutics operates under Healthcare sector and is part of Biotechnology industry. The entity has 249.59 M outstanding shares.
Egetis Therapeutics AB has accumulated about 207.41 M in cash with (130.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.26.
Check Egetis Therapeutics Probability Of Bankruptcy
Ownership AllocationEgetis Therapeutics retains a total of 249.59 Million outstanding shares. Egetis Therapeutics AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Egetis Ownership Details
Egetis Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Egetis Therapeutics jumping above the current price in 90 days from now is about 29.74%. The Egetis Therapeutics AB probability density function shows the probability of Egetis Therapeutics stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Egetis Therapeutics has a beta of 0.7407 suggesting as returns on the market go up, Egetis Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Egetis Therapeutics AB will be expected to be much smaller as well. Additionally, egetis Therapeutics AB has an alpha of 0.1193, implying that it can generate a 0.12 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Egetis Therapeutics to move above the current price in 90 days from now is about 29.74 (This Egetis Therapeutics AB probability density function shows the probability of Egetis Stock to fall within a particular range of prices over 90 days) .
Egetis Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Egetis Therapeutics market risk premium is the additional return an investor will receive from holding Egetis Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Egetis Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Egetis Therapeutics' alpha and beta are two of the key measurements used to evaluate Egetis Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.44 | |||
| Semi Deviation | 2.46 | |||
| Standard Deviation | 3.6 | |||
| Variance | 12.96 |
Egetis Stock Against Markets
Picking the right benchmark for Egetis Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Egetis Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Egetis Therapeutics is critical whether you are bullish or bearish towards Egetis Therapeutics AB at a given time. Please also check how Egetis Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Egetis Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Egetis Therapeutics Corporate Management
Elected by the shareholders, the Egetis Therapeutics' board of directors comprises two types of representatives: Egetis Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Egetis. The board's role is to monitor Egetis Therapeutics' management team and ensure that shareholders' interests are well served. Egetis Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Egetis Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Torsten Almn | Founder | Profile | |
| Louis Ignarro | Founder | Profile | |
| Rob Towart | Founder | Profile | |
| Associate Brurok | Founder | Profile | |
| Yilmaz Mahshid | Chief Officer | Profile | |
| Ingemar Lundstrm | Founder | Profile | |
| MBA MBA | Chief Officer | Profile |
How to buy Egetis Stock?
Before investing in Egetis Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Egetis Therapeutics. To buy Egetis Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Egetis Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Egetis Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Egetis Therapeutics AB stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Egetis Therapeutics AB stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Egetis Therapeutics AB, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Egetis Therapeutics AB?
The danger of trading Egetis Therapeutics AB is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Egetis Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Egetis Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Egetis Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Egetis Therapeutics AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Egetis Stock analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |